Table 2.

Univariate competing-risks regression analysis of cardiovascular death in PCNSLs.

Variable	Before PSM		After PSM
	HR (95% CI)	P Value	HR (95% CI)	P Value
Chemotherapy		0.014		0.010
Yes	0.476 (0.262–0.862)	0.014	0.445 (0.240–0.824)	0.010
No evidence	Reference		Reference
Age at diagnosis		0.001		0.007
≤60 years	Reference		Reference
>60 years	3.248 (1.583–6.664)	0.001	2.854 (1.331–6.117)	0.007
Sex		0.062		0.151
Male	Reference		Reference
Female	1.727 (0.974–3.064)	0.062	1.556 (0.851–2.846)	0.151
Race		0.492		0.742
White	Reference		Reference
Black	0.271 (0.034–1.959)	0.196	0.310 (0.043–2.252)	0.247
Others#	0.850 (0.363–1.994)	0.709	0.989 (0.418–2.338)	0.980
Marital status		0.151		0.069
Married	1.575 (0.847–2.926)	0.151	1.889 (0.953–3.746)	0.069
Unmarried	Reference		Reference
Year of diagnosis		0.019		0.070
2004–2009	Reference		Reference
2010–2015	0.487 (0.267–0.889)	0.019	0.560 (0.299–1.048)	0.070
Tumor location		0.362		0.668
Brain	Reference		Reference
Spine	1.642 (0.504–5.350)	0.411	0.814 (0.110–6.016)	0.840
NOS*	1.373 (0.585–3.224)	0.466	1.305 (0.471–3.611)	0.609
Histological type		0.498		0.706
Mature B-cell NHL	Reference		Reference
Others$	1.279 (0.628–2.604)	0.498	1.180 (0.500–2.784)	0.706
Surgery		0.681		0.873
Yes	0.887 (0.502–1.568)	0.681	0.952 (0.520–1.744)	0.873
No evidence	Reference		Reference

^#Others include American Indian/Alaska Native and Asian/Pacific Islander.

*Not specific primary site of central nerve system.

^$Others include peripheral T-cell lymphoma, anaplastic large cell lymphoma, extranodal NK-/T-cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, precursor B-lymphoblastic lymphoma, precursor T-cell lymphoblastic lymphoma and not specific non-Hodgkin’s lymphoma. The bold values mean P value < 0.05.

NOS, not otherwise specific; PSM, propensity score matching; 95% CI, 95% confidence interval.